Compare Abbott Laboratories (ABT) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Church & Dwight Co., Inc. — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Church & Dwight Co., Inc. trades at $96.07 (market cap $23.45B). The key difference: Abbott Laboratories is far larger — about 7.1× Church & Dwight Co., Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CHD | |
|---|---|---|
Market Cap | $166.94B | $23.45B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $105.26 |
52-Week Low | $82.57 | $81.60 |
Enterprise Value | $193.69B | $25.15B |
Dividend Yield | 2.63% | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Church & Dwight (CHD) trades at $98.95, up 0.35% with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q1 2026 adjusted EPS of $0.95 beating the $0.93 estimate (Zacks Investment Research, 2026-05-01). Recent acquisition of Miss Mouth's brand for $325 million strengthens its fabric care portfolio. Valuation metrics show a P/E of 32.43 and ROE of 16.78%, indicating premium pricing but strong profitability.
Outlook remains positive with 53% analyst buy ratings and a $100.50 consensus target, though net cash flow turned negative in 2025. Risks include cost pressures impacting margins, as seen in Q1 profit slippage (WSJ, 2026-05-01), and high debt levels. The stock offers growth potential through organic sales expansion and strategic acquisitions, but investors should monitor margin sustainability and competitive dynamics in consumer staples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
